These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 9464821

  • 1. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP, Liautard J, Klein B, Brochier J.
    Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-6 receptor signaling. II. Bio-availability of interleukin-6 in serum.
    Gaillard J, Pugnière M, Tresca J, Mani J, Klein B, Brochier J.
    Eur Cytokine Netw; 1999 Sep; 10(3):337-44. PubMed ID: 10477390
    [Abstract] [Full Text] [Related]

  • 3. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
    Lasfar A, Wietzerbin J, Billard C.
    Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
    [Abstract] [Full Text] [Related]

  • 4. Soluble interleukin-6 receptor alpha inhibits the cytokine-Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture.
    Matsumiya T, Imaizumi T, Fujimoto K, Cui X, Shibata T, Tamo W, Kumagai M, Tanji K, Yoshida H, Kimura H, Satoh K.
    Exp Cell Res; 2001 Sep 10; 269(1):35-41. PubMed ID: 11525637
    [Abstract] [Full Text] [Related]

  • 5. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
    Ganapathi MK, Weizer AK, Borsellino S, Bukowski RM, Ganapathi R, Rice T, Casey G, Kawamura K.
    Cell Growth Differ; 1996 Jul 10; 7(7):923-9. PubMed ID: 8809410
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
    Gaillard JP, Mani JC, Liautard J, Klein B, Brochier J.
    Eur Cytokine Netw; 1999 Mar 10; 10(1):43-8. PubMed ID: 10210772
    [Abstract] [Full Text] [Related]

  • 7. Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage.
    Thabard W, Barillé S, Collette M, Harousseau JL, Rapp MJ, Bataille R, Amiot M.
    Clin Cancer Res; 1999 Oct 10; 5(10):2693-7. PubMed ID: 10537331
    [Abstract] [Full Text] [Related]

  • 8. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
    Barillé S, Collette M, Thabard W, Bleunven C, Bataille R, Amiot M.
    Cytokine; 2000 Sep 10; 12(9):1426-9. PubMed ID: 10976008
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes.
    Gabay C, Silacci P, Genin B, Mentha G, Le Coultre C, Guerne PA.
    Eur J Immunol; 1995 Aug 10; 25(8):2378-83. PubMed ID: 7545121
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer.
    Rose-John S, Scheller J, Elson G, Jones SA.
    J Leukoc Biol; 2006 Aug 10; 80(2):227-36. PubMed ID: 16707558
    [Abstract] [Full Text] [Related]

  • 12. Factors influencing the effect of the soluble IL-6 receptor on IL-6 responses in HepG2 hepatocytes.
    Paysant J, Blanqué R, Vasse M, Soria C, Soria J, Gardner CR.
    Cytokine; 2000 Jun 10; 12(6):774-9. PubMed ID: 10843763
    [Abstract] [Full Text] [Related]

  • 13. Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor.
    Karadag A, Scutt AM, Croucher PI.
    J Bone Miner Res; 2000 Oct 10; 15(10):1935-43. PubMed ID: 11028445
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of interleukin-6-transsignaling via gp130-Fc in hemorrhagic shock and sepsis.
    Mees ST, Toellner S, Marx K, Faendrich F, Kallen KJ, Schroeder J, Haier J, Kahlke V.
    J Surg Res; 2009 Dec 10; 157(2):235-42. PubMed ID: 19589542
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H, Wiersbowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2000 Sep 10; 11(3):443-51. PubMed ID: 11022130
    [Abstract] [Full Text] [Related]

  • 17. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses.
    Müller-Newen G, Küster A, Hemmann U, Keul R, Horsten U, Martens A, Graeve L, Wijdenes J, Heinrich PC.
    J Immunol; 1998 Dec 01; 161(11):6347-55. PubMed ID: 9834125
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
    Peters M, Blinn G, Solem F, Fischer M, Meyer zum Büschenfelde KH, Rose-John S.
    J Immunol; 1998 Oct 01; 161(7):3575-81. PubMed ID: 9759879
    [Abstract] [Full Text] [Related]

  • 20. IL-6 transsignaling: the in vivo consequences.
    Jones SA, Richards PJ, Scheller J, Rose-John S.
    J Interferon Cytokine Res; 2005 May 01; 25(5):241-53. PubMed ID: 15871661
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.